Restricted accessResearch articleFirst published online 1999-09
Year 2000 guidelines for the use of antimicrobial agents in adult and pediatric neutropenic patients with unexplained fever from the Universities of Lübeck and Kiel
Cornely OA, Hiddemann W, Link H, et al.The study group of the PEG. Interventional antimicrobial therapy in febrile neotropenic patients—Paul Ehrlich Society for Chemotherapy (PEG) study II. Ann Hematol. 1997;74(suppl 1):51-64.
2.
Pizzo PA.Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med. 1993;328:1323-1332.
3.
Maschmeyer G, Link H, Hiddemann W, et al.Pulmonary infiltrations in febrile patients with neutropenia. Cancer. 1994;73:2296-2304.
4.
Paterson DL, Singh N.Invasive aspergillosis in transplant recipients. Medicine. 1999;78:123-138.
5.
Hughes WT, Pizzo PA, Wade JC, Armstrong D, Webb CD, Young LS.Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Clin Infect Dis. 1992;15: 206-215.
6.
International Antimicrobial Therapy Cooperative Group of the EORTC. Efficacy and safety of a single daily dose of amikacin and ceftriaxone versus amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med. 1993;119:584-592.
7.
Klastersky J, Glauser MP, Schimpff SC, Zinner SH, Gaya H.Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients. Antimicrob Agents Chemother. 1986; 29:263-270.
8.
Cometta A, Zinner S, deBock R, et al.Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother. 1995;39:445-452.
9.
Behre G, Link H, Maschmeyer G, et al.Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients. Ann Hematol. 1998;76:73-80.
10.
Hess U, Böhme C, Rey K, Senn HJ.Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients. Support Care Cancer1998;6:402-409.
11.
Kieft H, Herbrecht R, Pico JL.Cefepime compared with ceftazi-dime as initial therapy for serious bacterial infections and sepsis syndrome. Antimicrob Agents Chemother. 1994;38:415-421.
12.
EORTC International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. Vancomycin added to empirical combination therapy for fever in granulocytopenic cancer patients. J Infect Dis. 1991;163:951-958.
13.
Novakova IRO, Donnelly JP, Verhagen CS, dePauw BE.Teicoplanin as modification of initial empirical therapy in febrile granulocytopenic patients. J Antimicrob Chemother. 1990;25:985-993.
14.
Hughes WT, Armstrong D, Bodey GP, et al.Guidelines from the Infectious Diseases Society of America: 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis. 1997;25:551-573.
15.
Richardson MD, Kokki MH.Antifungal therapy in bone marrow failure. Br J Haematol. 1998;100:619-628.
16.
Walsh TJ, Finberg RW, Arndt C, et al.Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999;340:764-771.
17.
Kennedy CA, Adams GL, Neglia JP, Glebink GS.Impact of surgical treatment on paranasal fungal infections in bone marrow transplant patients. Otolaryngol Head Neck Surg. 1997;116:610-616.
18.
Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol. 1996;14:1957-1960.
